$130 Billion Biopharma Deal Spree Driven by Patent Cliff Fears

Big Pharma has spent nearly $130 billion on biopharma deals in the first half of 2026, just shy of last year's total. This spending spree is largely driven by companies scrambling to replace revenue gaps caused by looming patent expirations. According to IQVIA, there have been 42 major transactions so far this year, with an average deal size of $3.1 billion.

The primary catalyst for these deals is the impending loss of exclusivity (LOE) on blockbuster drugs maturing before 2030. Pharmaceutical giants are buying up late-stage assets to replace revenue lost when key patents expire. For example, Merck's acquisition of Terns Pharmaceuticals includes the experimental leukemia drug TERN-701, which is in Phase 1/2 clinical trials.

Other notable deals include GSK's $10.6 billion purchase of Nuvalent and Eli Lilly's $7.8 billion acquisition of Centessa Pharmaceuticals. These transactions demonstrate a shift towards buying larger, more established assets with proven clinical efficacy or pending regulatory clearance.